Literature DB >> 3135052

Alcohol and response to treatment of gout.

S H Ralston1, H A Capell, R D Sturrock.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3135052      PMCID： PMC2546167          DOI： 10.1136/bmj.296.6637.1641-a

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN： 0267-0623


× No keyword cloud information.
  3 in total

1.  Clinical survey of 354 patients with gout.

Authors:  R Grahame; J T Scott
Journal:  Ann Rheum Dis       Date:  1970-09       Impact factor: 19.103

2.  Moonshine and lead. Relationship to the pathogenesis of hyperuricemia in gout.

Authors:  P P Reynolds; M J Knapp; H S Baraf; E W Holmes
Journal:  Arthritis Rheum       Date:  1983-09

3.  Ethanol-induced hyperuricemia: evidence for increased urate production by activation of adenine nucleotide turnover.

Authors:  J Faller; I H Fox
Journal:  N Engl J Med       Date:  1982-12-23       Impact factor: 91.245
  3 in total
  8 in total

1.  Gout. Easy to misdiagnose.

Authors:  R D Sturrock
Journal:  BMJ       Date:  2000-01-15

Review 2.  Compliance in clinical trials.

Authors:  T Pullar; S Kumar; M Feely
Journal:  Ann Rheum Dis       Date:  1989-10       Impact factor: 19.103

3.  Expert consensus for the diagnosis and treatment of patient with hyperuricemia and high cardiovascular risk: 2021 update.

Authors:  Claudio Borghi; Justyna Domienik-Karłowicz; Andrzej Tykarski; Krystyna Widecka; Krzysztof J Filipiak; Miłosz J Jaguszewski; Krzysztof Narkiewicz; Giuseppe Mancia
Journal:  Cardiol J       Date:  2021-01-13       Impact factor: 2.737

Review 4.  Role of diet in hyperuricemia and gout.

Authors:  Abhijeet Danve; Shiv Tej Sehra; Tuhina Neogi
Journal:  Best Pract Res Clin Rheumatol       Date:  2021-11-19       Impact factor: 4.098

5.  Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout.

Authors:  F Perez-Ruiz; A Alonso-Ruiz; M Calabozo; A Herrero-Beites; G García-Erauskin; E Ruiz-Lucea
Journal:  Ann Rheum Dis       Date:  1998-09       Impact factor: 19.103

Review 6.  Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol.

Authors:  Richard O Day; Garry G Graham; Mark Hicks; Andrew J McLachlan; Sophie L Stocker; Kenneth M Williams
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 7.  A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients?

Authors:  Ming-Han H Lee; Garry G Graham; Kenneth M Williams; Richard O Day
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

Review 8.  Gout in the elderly. Clinical presentation and treatment.

Authors:  A G Fam
Journal:  Drugs Aging       Date:  1998-09       Impact factor: 4.271
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.